GGAATTCCATATGCGTATTTTGTTTGTAGGCCCGC-3') and a reverse primer (5'-GATCGAATTCGGCCCTTTCTGTACCATTGTGATCAGG -3') that resulted in the introduction of NdeI and EcoRI restriction sites (underlined) upstream and downstream of the iroB open reading frame, respectively. Amplification was performed using iProof DNA polymerase (Bio-Rad Laboratories) according to the protocol supplied by the manufacturer.
After digestion of the PCR product and expression vector pET24b (Novagen) with NdeI and EcoRI, the insert was ligated into the vector under control of a T7 promoter in-frame with a Cterminal hexahistidine affinity tag. The resulting vector, pET24b-iroB-CH6, was transformed into DH5α and identity was verified by DNA sequencing (Genome Quebec Innovation Centre,
McGill University).

Site-directed mutagenesis
Site-directed mutagenesis of iroB was performed using the QuikChange Site-Directed Mutagenesis Kit (Stratagene) using pET24b-iroB-CH6 as a template along with a pair of customsynthesized mutagenic oligonucleotide primers for each mutant generated. The mutagenic oligonucleotides were designed to substitute the following IroB residues: (i) Trp264 to Leu (W264L): forward primer (5'-GTTCGCCTGGTTGACTTGATACCCATGGGTGTC-3'), reverse primer (5'-GACACCCATGGGTATCAAGTCAACCAGGCGAAC-3'); (ii) Glu67 to Ala (E67A): forward primer (5'-GTTACCGCCACCATGCGGCACAGCGGAAAAA-3'), reverse primer: 5'-TTTTTCCGCTGTGCCGCATGGTGGCGGTAAC-3'); (iii) Asp304 to Asn (D304N):
forward primer (5'-GGCCAGGGAGCCAATCGCCCGGTAA-3'), reverse primer (5'-TTACCGGGCGATTGGCTCCCTGGCC-3'); (iv) His65 to Ala and His66 to Ala (H65A/H66A):
forward primer (5'-CCGAAGCTGGTTACCGCGCCGCTGAGGCACAGCGGAAAA-3'), reverse primer (5'-TTTTCCGCTGTGCCTCAGCGGCGCGGTAACCAGCTTCGG-3').
Mutagenesis reaction mixtures (50 µl) contained: pET24b-IroB-CH6 template DNA (~ 2 µg/µl), mutagenic forward and reverse primers (0.5 µM each), dNTP mixture (0.2 mM each of dATP, dTTP, dCTP, and dGTP), and PfuTurbo DNA polymerase (0.05 U/µl). The number, duration, and temperature of the PCR cycles were performed according to the manufacturer's instructions.
Prior to transformation into DH5α, parental vectors were digested with DpnI. Double-stranded plasmids obtained from site directed mutagenesis were purified and variant identities were verified by DNA sequencing (Genome Quebec Innovation Centre, McGill University).
Expression and purification of IroB-CH6 and variant proteins
Expression constructs (pET24b-IroB-CH6) containing DNA sequences encoding in-frame Cterminal hexahistidine-tagged wild-type IroB (henceforth referred to as IroB-CH6) or IroB-CH6 variants (W264L, E67A, D304N, H65A/H66A) were transformed into competent E. coli BL21-DE3 cells (Novagen). Transformants were grown in 2xYT broth containing 30 µg/ml of kanamycin at 37 °C to an OD 600 of ~0.6. Protein expression was induced with the addition of IPTG to a final concentration of 0.4 mM followed by further incubation in a platform shaker (220 RPM) at 20 o C for 20 hours. Cells were pelleted by centrifugation (6,000 g) and stored at -20 o C until required. For purification, cell pellets from 1 L culture were resuspended in 30 ml ice-cold Buffer A (20 mM Tris (pH 8.5), 500 mM NaCl, 20 mM imidazole, 500 mM sucrose, 2 mM TCEP) supplemented with Protease Inhibitor Cocktail (BioShop, Inc.). Cell lysis was achieved after three passes in a French pressure cell operated at 16,000 to 18,000 lb in -2 . Cell lysates were kept cold during this procedure. Insoluble matter and cell debris were removed by ultracentrifugation at 130,000 g for 1 h at 4 °C. Clarified lysates were applied to a 10 ml Ni-NTA 
Circular dichroism spectroscopy
Far-UV CD spectra of purified IroB-CH6 and variant protein samples were collected on a Jasco J-815 circular dichroism spectropolarimeter. Purified proteins were dialyzed into Buffer C and then diluted to a concentration of 4.7 µM in the same buffer. Diluted samples were loaded into a rectangular cell with 0.1 cm path length and spectra were recorded at 20 °C by averaging five wavelength scans (1 nm bandwidth) from 260 nm to 200 nm (step size: 0.2-nm, scan rate: 20 nm/min). Spectra were corrected for buffer contributions, smoothed and signals were converted to molar ellipticities using the instrument software package. Final spectra were exported and plotted using OriginLab (version 8.6).
For thermal stability experiments, ellipticities at 222 nm were monitored between 20 o C and 98 o C (rate of temperature change: 0.5 o C min -1 ) using a Jasco J-815 CD spectropolarimeter with a temperature-controlled cell holder. Thermal denaturation data were normalized in terms of fraction of folded protein at each temperature value by assigning the ellipticity value at 20 °C to 100% folded (fraction folded = 1) and the value at 60 °C to 100% unfolded (fraction folded = 0).
The melting temperature (T m ) was determined from thermal denaturation curves by using the first derivative function of the instrument's software package, where maxima between 20 °C and 60 °C was used to determine T m values. All CD spectra of protein solutions were corrected for contributions of buffer components using spectra collected in the absence of protein.
Fluorescence spectroscopy
Fluorescence spectroscopy was used to assess the tertiary structure of purified IroB-CH6 and variants. Spectra were recorded at room temperature using a Varian Cary Eclipse spectrofluorometer with the Varian Scan program (version 1.1). For fluorescence experiments, protein concentrations were diluted to avoid inner filter effects such that OD 280 values were always below 0.05. Purified IroB-CH6 and variant protein concentrations were adjusted to 1 µM in Buffer A. Samples were loaded into a 1 cm Varian fluorescence cuvette, and fluorescence emission spectra were collected from 300 to 400 nm using excitation wavelengths of 280 nm or 295 nm. All spectra were recorded in CAT mode (reported spectra are averages of 10 scans each), excitation and emission slit width were set to 5 nm, the voltage and scan speed adjusted to 600 V and 600 nm min -1 , respectively. Spectra were corrected for buffer contribution by subtraction of signal from spectra collected on protein-free samples using the instrument's calculation software. Scan data were exported and analyzed using OriginLab.
IroB-CH6 activity assay
The HPLC-based IroB activity assay used in this study was adapted from Fischbach et al. 9 IroB-CH6 and variant proteins were exchanged into Buffer D (75 mM HEPES (pH 7.5), 50% glycerol (v/v), 2.5 mM TCEP) using a DG10 desalting column, and concentrations of exchanged proteins were determined spectrophotometrically at 280 nm using molar extinction coefficients predicted from primary amino acid sequences. Fluorescence intensities were corrected for inner filter effects according to the equation:
where F obs is the observed fluorescence intensity, OD ex is the observed absorbance at the excitation wavelength, OD em is the observed absorbance at the emission wavelength.
The ratio of initial fluorescence intensities to fluorescence intensities at given enterobactin concentrations were plotted as a function of enterobactin concentration according to the SternVolmer 18 equation:
where 
Results
Homology modeling of E. coli IroB reveals candidate residues involved in catalysis
In order to locate the IroB active site in the absence of structural data, we used homology modeling to predict the three-dimensional structure of the protein. We identified crystallized orthologues as candidate templates for homology modeling via the PDB search function of the FFAS03 server. 12 Our FFAS03 search reported the C-glycosyltransferase UrdGT2 (PDB code:
2P6P) 19 and the C-glycosyltransferase SsfS6 from Streptomyces sp. (PDB code: 4G2T) 20 as the C-GT orthologues with the highest degree of structural alignment. We therefore used 2P6P and 4G2T as templates for homology modeling using Modeller v9. 13 and obtained an IroB model that superimposed well with the structures of 2P6P and 4G2T (superposition RMSD values:
1.00 Å and 0.593 Å, respectively) ( Fig. 3a) . Evaluation by PROCHECK 15 and ProSA-Web 279-WVPQ-282 was found to structurally align with IroB residues 264-WIPM-267 (Fig. 3c ). In the CalG1 structure, residue W279 is involved in a stacking interaction with the thymidine base of TDP. IroB residue W264 superimposes with CalG1 W279, suggesting that W264 can form a similar stacking interaction with the uridine base of UDP-glucose. Given the predicted position of the binding site for UDP-glucose in our IroB model, we were able to infer the location of the acceptor-binding site, which would be proximal to the glucose moiety of UDP-glucose, at the cleft between the N-and C-terminal domains. IroB residue D304 is found at this cleft in our model, at a position that suggests a possible role in stabilizing the glucose moiety of the nucleotide cofactor. Our model also indicated the presence of a hydrophobic cluster near D304, consisting of IroB residues L10, L13, and L110 (not shown in Fig. 3 ), that could be involved in a hydrophobic interaction with the bound acceptor. Near this hydrophobic cluster, we found a long loop between residues 56-69 that could potentially close over the predicted acceptor-binding site.
Possible catalytic residues on this loop that could participate in deprotonation of acceptor DHB moieties were identified: H65, H66 and E67. These three residues, as well as the predicted UDPglucose-binding residues D304 and W264, were changed by site-directed mutagenesis to gain insights into their roles in IroB catalysis and substrate binding. Three of the five residues were altered to produce single-site IroB variant proteins: E67A, W264L, D304N. The histidine residues at positions 65 and 66 were changed to produce a double-site IroB variant protein:
H65A/H66A.
Expression and purification of IroB-CH6 and variant proteins
We initially attempted to purify IroB-CH6 according to a previously reported approach 9 , which led to heavy IroB-CH6 precipitation at higher concentrations. We were able to optimize IroB- of recombinant IroB-CH6 per liter of culture, and this optimized protocol was also used to purify the IroB-CH6 variants that we generated. Purities of IroB-CH6 and variant preparations were found to be comparable, and were estimated to be ≥85% based on densitometry following SDS-PAGE (not shown).
Structural integrity of IroB-CH6 and variant proteins
To assess overall protein fold qualities, we examined our purified IroB-CH6 and variant proteins using several biophysical methods that are sensitive to secondary structure (far-UV circular dichroism (CD)), overall stability (thermal denaturation measured by far-UV CD) and tertiary structure (fluorescence spectroscopy). Our far-UV CD analyses (Fig. 4a) indicate that IroB-CH6
and variant proteins were folded with similar secondary structure contents. The spectrum of IroB-CH6 (WT) ( 
Fluorescence emission spectra
Fluorescence spectroscopy was used to further probe the tertiary structures of IroB-CH6 and variant proteins. The fluorescence emission spectra of wild-type IroB-CH6 upon excitation at 280 nm (Fig. 5a , black dashed trace) and 295 nm (Fig. 5a , black solid trace) exhibited emission maxima at 345 nm, suggesting that at least some of the eight tryptophan residues in wild-type IroB-CH6 are found in a polar environment, and are likely solvent-exposed. The fluorescence emission spectra (dashed traces: λ ex = 280 nm; solid traces: λ ex = 295 nm) of the IroB variants D304N (Fig. 5a , magenta traces), E67A (Fig. 5a , red traces) and H65A/H66A (Fig. 5a, green traces) all superimpose with those of IroB-CH6. In contrast, peaks of the fluorescence emission spectra of W264L (Fig. 5b , blue traces) exhibited a blue shift relative to those of IroB-CH6 (Fig.   5b , black traces), consistent with W264 occurring in a more polar environment.
Enzymatic activities of IroB-CH6 and variant proteins
Based on our homology modelling and bioinformatics analyses, we predicted that IroB residues H65, H66, and E67 could potentially function as catalytic residues involved in deprotonation, while D304 and W264 could potentially be involved in UDP-glucose binding. We therefore incubated wild-type IroB-CH6 and our four variant proteins under identical assay conditions to compare levels of enzymatic activities. Under these conditions, we expected the wild-type enzyme to completely convert enterobactin predominantly to DGE, which has been shown to be the predominant biological product. 5 We employed an HPLC-based activity assay modified from
Fischbach et al. 9 to measure the relative activities of IroB-CH6 and variant proteins. Reactant and product (enterobactin, MGE, DGE, TGE) identities were confirmed by inline ESI-MS analysis of eluted species from a quenched IroB-CH6 reaction mixture separated by RP-HPLC.
Good correspondences (within 0.5 Da) were observed between expected and observed masses for all species, thus confirming their identities (Table 2) . Chromatographic traces of IroB-CH6
and variant assay reactions quenched at 60 min are shown in Figure 6 , where the relative abundances of reactants and products were calculated by integration of areas and shown above respective chromatographic peaks. As expected, wild-type IroB-CH6 converted 100% of the enterobactin substrate to DGE (88%) and TGE (12%) after 60 min (Fig. 6a) . W264L, which our model predicted to stack with the uridine base of the UDP-glucose donor, was only able to convert 55% of total enterobactin substrate to MGE (45%) and DGE (10%) (Fig. 6b) . The D304N variant, which we predicted to be proximal to the enterobactin-binding site and the glucose moiety of UDP-glucose, was found to be completely inactive in our assay (Fig. 6c) . The variant E67A, which our model predicted to be located on a loop near the enterobactin-binding site, was able to partially convert enterobactin to MGE (29%), leaving 71% of the substrate unconverted (Fig. 6d) . Finally, we found the double variant H65A/H66A to be active, converting 92% of enterobactin to glycosylated products; however, in contrast to IroB-CH6, the double variant produced more MGE (60%) than DGE (32%) (Fig 6e) .
Enterobactin binds to IroB variants
IroB variants W264L, D304N, E67A and H65A/H66A exhibited partial or complete loss of enzymatic activity with respect to enterobactin conversion. We therefore wanted to determine if the observed decreases in activities were due to an inability of the variants to bind the substrate enterobactin. Enterobactin has been previously shown to statically quench IroB intrinsic fluorescence upon binding, such that the quenching effect can be used to measure enterobactin binding to IroB. 17 Here we titrated IroB-CH6 and variant proteins with pure enterobactin up to a concentration of 10 µM. Over this concentration range, increases in Fo/F as a function of correlates with quencher binding affinity. 18 Using this approach, we found that IroB-CH6 and all variant proteins were able to bind enterobactin with affinities within 2.5-fold of IroB-CH6 (Fig.   7 ). Binding of enterobactin to wild-type IroB-CH6 resulted in a K SV value of 0.16 µM -1 (Fig. 7a) .
The variants W264A and D304N, residues that we predict to be involved in UDP-glucose binding, were found to have the lowest K SV values, and thus the lowest affinities: 0.080 µM -1 and 0.069 µM -1 , respectively (Fig. 7b-c) . The variants E67A and H65A/H66A, predicted to be on a mobile loop that closes over the IroB active site, were found to bind enterobactin with affinities (K SV = 0.14 µM -1 and 0.12 µM -1 , respectively) similar to IroB-CH6 (Fig 7d-e) .
Discussion
The enterobactin-modifying enzyme IroB from E. coli belongs to a relatively rare class of glycosyltransferases that attach glucose moieties to acceptor molecules via formation of C-C bonds. Previous studies on IroB have shown that it catalyzes the formation of MGE followed by conversion of MGE to DGE, with relatively little TGE being produced in vivo. 5, 9 Little is currently known about the mechanism of this enzyme, including knowledge of specific residues involved in substrate binding and catalysis. This lack of data may be in part due to the difficult nature of isolating this protein under conditions optimal for in vitro studies. Our expression and purification of recombinant IroB-CH6 was initially hampered by its tendency to partition in the insoluble phase upon centrifugation of cell lysates, and to precipitate above ~0.3 mg ml -1 during purification. We found that IroB-CH6 solubility and conformational stability were greatly improved in the presence of a number of different osmolytes, including glycerol, trehalose, and sucrose. Since we found that these osmolytes enhanced the folded state of the protein, we used sucrose (0.5-1.0 M) or relatively high concentrations of glycerol (~ 50%) to assist in stabilizing purified IroB-CH6 and variant proteins in vitro. suggesting that these proteins are responsive to the physiological environment of the cytoplasm. 23, 24 Perhaps proteins of the functionally-related iroA cluster, such as IroB, are similarly responsive to their intracellular contexts. We are now further exploring this possibility.
Such difficulties inherent in the handling of IroB in vitro
In order to find IroB catalytic residues, given that no structure of E. coli IroB has been found IroB residue W264 to be structurally conserved with CalG1 W279, which forms a stacking interaction with the thymidine base of co-crystallized TDP in the 3OTH structure. We therefore hypothesized that IroB W264 was involved in stabilization of the uridine base of UDP-glucose.
In support of this, our fluorescence spectroscopy experiments revealed a blue shift in the W264L
emission maximum compared to wild-type IroB, suggesting that W264 is solvent-exposed, consistent with its predicted location at the surface of the UDP-glucose binding site. Our W264L variant exhibited reduced (45%) activity compared to IroB-CH6 even though our biophysical characterizations indicated that this variant was well folded and could bind enterobactin with wild-type affinity. Taken together, these data support the hypothesized role of W264 in binding/positioning UDP-glucose as predicted by our homology model, thus contributing to validation of our IroB model.
Based on the assumption that IroB W264 is involved in UDP-glucose binding, we followed the orientation of the superimposed TDP cofactor from 3OTH in order to gain insights into the binding site of the acceptor molecule. Proximal to the predicted glucose moiety of UDPglucose lies IroB residue D304, which is located at the cleft of the N-and C-terminal domains.
Given its location, D304 could participate in coordinating the glucose moiety of UDP-glucose, or it could participate in proton abstraction from a DHB group on the bound acceptor. Many structures of glycosyltransferase enzymes have been reported to have a catalytic aspartate residue at the interdomain cleft of the GT fold, with the aspartate participating in a catalytic dyad with a nearby histidine residue. 21 Our IroB model indicates the presence of H138 within hydrogenbonding distance of D304, but an H138A variant that we generated retained full enzymatic activity (data not shown). Furthermore, the UrdGT2 catalytic dyad comprised of Asp 137 and the backbone amide of Val139 is located within the UrdGT2 interdomain cleft, but the C β -C β distance between IroB D304 and UrdGT2 D137 in the superimposed structures is 8.86 Å, demonstrating that these residues are therefore not at structurally-conserved positions. To investigate a possible role for D304 in IroB catalysis, we changed this residue to asparagine. We observed that the D304N variant had no detectable activity under our assay conditions, even though D304N was found to be well folded and could bind enterobactin. It is therefore likely that the role of IroB D304 is in stabilizing the glucose moiety of UDP-glucose during catalysis. In support of this, Offen et al. demonstrated that D374 in the O-glycosyltransferase VvGT1 (PDB code: 2C1Z) from Vitis vinifera is involved in coordinating the glucose moiety of the sugar donor by hydrogen bonding to 3-OH and 4-OH of glucose via the D374 carboxyl group. 25 The D374A mutation in VvGT1 reduced catalytic activity to a non-detectable level, consistent with what we observed in our IroB D304N variant activity assay. Amino acid sequence alignment of VvGT1 with IroB shows that VvGT1 D374 and IroB D304 share a position of sequence identity (Fig. S1 ). We therefore propose that D304 is involved in the orientation of the glucose moiety of UDP-glucose rather than in acceptor deprotonation. To investigate this further, we are currently working towards optimizing our purification and IroB stabilization methods to allow for higher protein concentrations that would facilitate direct calorimetric binding assays of UDP-glucose to IroB-CH6 in comparison with the W264L and D304N variants.
If D304 is indeed positioned to stabilize glucose, then our model predicts that IroB E67
would likely be a base catalyst participating in deprotonation of DHB groups on the bound acceptor. In our model, E67 is located on a loop between IroB residues 56 and 69. This region of IroB is not conserved among GT orthologues (Fig. S1 ), providing support that E67 is indeed found in a loop. The lack of sequence conservation is also consistent with its proposed role in acceptor molecule interaction, given the heterogeneity of GT acceptor molecules. Based on its position in our IroB model relative to the predicted acceptor-binding site, we hypothesize that the 56-69 loop containing E67 is mobile, being able to close over the acceptor molecule upon its binding. Prior experimental data reported on similar enzymes support a catalytic role for such a loop in IroB. Hoffmeister and coworkers identified a region between residues 52 and 82 that confers substrate specificity for the conserved C-glycosyltransferases UrdGT1b and UrdgGT1c. 26, 27 Furthermore, the UrdGT2 structure (PDB code: 2P6P) revealed a structurally conserved loop comprised of UrdGT2 residues 62-72 that is adjacent to the acceptor-binding site. This loop has been proposed to close over the acceptor molecule upon binding so that a base catalyst (either UrdGT2 E66 or E71) could fulfill its function. 19 Similar to the position of UrdGT2 E71, the location of IroB E67 in a predicted mobile loop in our model supports its role as a base catalyst in the deprotonation of bound acceptor. We found that mutation of E67 to alanine had a severe impact on IroB catalysis: 70% of enterobactin substrate remained unconverted, and only MGE could be produced. As with D304N, we found the E67A variant to be properly folded and it could bind to enterobactin with wild-type affinity. This demonstrates that the E67A mutation exclusively affects catalytic function. Fischbach et al. reported that the IroB mechanism is distributive, with accumulation of MGE followed by subsequent accumulation of DGE, and then finally of TGE. This study further suggested that carbanion formation at the C5 of the acceptor DHB moiety, where C-glucosylation occurs, requires prior deprotonation of the DHB C2-OH group, which is para to C5. 9 Residue E67 may be involved in deprotonation at the DHB C2-OH position since the C β -C β distance between E67 and D304 is 10.9 Å, with sufficient intervening space for a DHB moiety to be situated with its C2 atom closer to E67 and its C5 atom closer to D304. Contiguous to IroB E67 are the residues H65 and H66, also on the predicted mobile loop in our model. We generated the double variant H65A/H66A to test the roles of these residues in IroB catalysis. The impact of these mutations on catalytic activity was moderate in comparison to E67A: the H65A/H66A variant is still able to produce MGE (60%) and DGE (32%) upon converting ~ 90% of the enterobactin substrate. Given these data, and the positions of H65 and H66 in our homology model, these residues could be involved in stabilizing E67 in a deprotonated state, or perhaps enhancing the catalytic function of E67 by formation of H-bonds with other IroB residues upon loop closure. Furthermore, since E67A retained partial activity, it is possible that the nearby H65 residue, which also has its side chain oriented toward the predicted acceptor-binding site, could substitute as a less efficient base catalyst for DHB deprotonation in the absence of E67.
In support of our proposed roles for IroB residues W264, D304, H65, and H66, and E67, we determined that variant proteins with mutations at these positions could all bind enterobactin (Fig. 7) . We found that the poorest binders of enterobactin, W264L and D304N, had affinities that were approximately 2.5-fold lower than that of IroB-CH6. Interestingly, these are the two residues that we propose to be involved in binding UDP-glucose. It is possible that W264 and D304 may also directly interact with the enterobactin acceptor, especially D304 given its predicted location at the interdomain cleft. However, it is also possible that subtle conformational rearrangements caused by the W264L and D304N mutations at the UDPglucose-binding site are linked to conformational rearrangements at the enterobactin-binding site, resulting in the lower observed acceptor-binding affinity. We are now further investigating possible conformational linkage between IroB donor and acceptor binding sites. In any event, the extent of quenching that we observed for IroB-CH6 is consistent with the previously reported K D for enterobactin binding to IroB (2.3 µM). 17 Since the concentration of enterobactin used in our activity assays was 100 µM, a saturating concentration given our experimentally-determined enterobactin-binding data, the losses of enzymatic activities that we observed for our IroB variants (which all had K SV values within ~2.5-fold of IroB-CH6) were not due to lowered affinities for enterobactin binding.
In conclusion, we have identified three residues as being necessary for efficient IroB catalysis: E67, W264, and D304 (Fig. 8) . Mutations at these positions negatively affected enzymatic activities, but these losses of activity were not due to protein misfolding, nor to impaired enterobactin binding. Taken together, our homology model and experimental data indicate that E67 is likely involved in acceptor (enterobactin/MGE/DGE) deprotonation at the phenolic group on the C2 carbon of the DHB moiety para to the site of glucose attachment at C5, while W264 and D304 are likely involved in donor (UDP-glucose) orientation to facilitate IroB catalysis. Table 2 ). Peak identities, determined by mass spectrometry, are labeled. Relative abundances determined by peak area integration are shown as percentages. 
